Bloem BR, Okun MS, Klein C. Parkinson’s disease. The Lancet. 2021;397:2284–303.
Ovallath S, Deepa P. The history of parkinsonism: descriptions in ancient Indian medical literature. Mov Disord. 2013;28:566–8.
Parkinson J. An Essay on the Shaking Palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14:223–36.
Goetz CG. The history of Parkinson’s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2011;1:a008862–a008862.
Article PubMed PubMed Central Google Scholar
Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med. 2003;348:1356–64.
Article CAS PubMed Google Scholar
Collaborators GN. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459–80.
Papapetropoulos S, Adi N, Ellul J, Argyriou AA, Chroni E. A prospective study of familial versus sporadic Parkinson’s disease. Neurodegener Dis. 2007;4:424–7.
Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318:121–34.
Masato A, Plotegher N, Boassa D, Bubacco L. Impaired dopamine metabolism in Parkinson’s disease pathogenesis. Mol Neurodegener. 2019;14:35.
Article PubMed PubMed Central Google Scholar
Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. J Neurochem. 2016;139:318–24.
Article CAS PubMed Google Scholar
Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010;67:715–25.
Article PubMed PubMed Central Google Scholar
Braak H, Bohl JR, Müller CM, Rüb U, de Vos RAI, Del Tredici K. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov Disord. 2006;21:2042–51.
Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag A-E, Lang AE. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.
Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368–76.
Article CAS PubMed Google Scholar
Solari N, Bonito-Oliva A, Fisone G, Brambilla R. Understanding cognitive deficits in Parkinson’s disease: lessons from preclinical animal models. Learn Mem. 2013;20:592–600.
Schneider F, Althaus A, Backes V, Dodel R. Psychiatric symptoms in Parkinson’s disease. Eur Arch Psychiatry Clin Neurosci. 2008;258:55–9.
Pagano G, Niccolini F, Politis M. Imaging in Parkinson’s disease Clin Med (Lond). 2016;16:371–5.
Schapira AHV, Gu M, Taanman JW, Tabrizi SJ, Seaton T, Cleeter M, Cooper JM. Mitochondria in the etiology and pathogenesis of parkinson’s disease. Ann Neurol. 1998;44:S89–98.
Article CAS PubMed Google Scholar
Park J-S, Davis RL, Sue CM. Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives. Curr Neurol Neurosci Rep. 2018;18(5):21.
Article PubMed PubMed Central Google Scholar
Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology. 1996;47:161S.
Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR. Oxidative stress and Parkinson’s disease. Front Neuroanatomy. 2015;9:91.
Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? The Lancet Neurology. 2009;8:382–97.
Article CAS PubMed Google Scholar
Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19.
Article PubMed PubMed Central Google Scholar
Ambrosi G, Cerri S, Blandini F. A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease. J Neural Transm (Vienna, Austria : 1996). 2014;121:849–59.
van der Brug MP, Singleton A, Gasser T, Lewis PA. Parkinson’s disease: From human genetics to clinical trials. Sci Transl Med. 2015;7:205ps220.
Funayama M, Nishioka K, Li Y, Hattori N. Molecular genetics of Parkinson's disease: Contributions and global trends. J Hum Genet. 2022. https://doi.org/10.1038/s10038-022-01058-5.
McNaught KS, Olanow CW. Protein aggregation in the pathogenesis of familial and sporadic Parkinson’s disease. Neurobiol Aging. 2006;27:530–45.
Article CAS PubMed Google Scholar
Akhtar RS, Xie SX, Brennan L, Pontecorvo MJ, Hurtig HI, Trojanowski JQ, Weintraub D, Siderowf AD. Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer’s Pathology in Parkinson’s Disease Dementia. Mov Disord Clin Pract. 2016;3:367–75.
Article PubMed PubMed Central Google Scholar
Murphy MP, Bayir H, Belousov V, Chang CJ, Davies KJA, Davies MJ, Dick TP, Finkel T, Forman HJ, Janssen-Heininger Y, et al. Guidelines for measuring reactive oxygen species and oxidative damage in cells and in vivo. Nat Metab. 2022;4:651–62.
Article PubMed PubMed Central Google Scholar
Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8:464–74.
Article CAS PubMed Google Scholar
Braak H, Braak E. Pathoanatomy of Parkinson’s disease. J Neurol. 2000;247:II3–10.
Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL. Limitations of current Parkinson’s disease therapy. Ann Neurol. 2003;53(Suppl 3):S3-12; discussion S12-5.
Article CAS PubMed Google Scholar
Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323:548–60.
Verger A, Grimaldi S, Ribeiro MJ, Frismand S, Guedj E. Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field. Ann Neurol. 2021;90:711–9.
Article PubMed PubMed Central Google Scholar
Nerella SG, Singh P, Sanam T, Digwal CS. PET Molecular Imaging in Drug Development: The Imaging and Chemistry Perspective. Front Med (Lausanne). 2022;9:812270.
Lu FM, Yuan Z. PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases. Quant Imaging Med Surg. 2015;5:433–47.
PubMed PubMed Central Google Scholar
Ametamey SM, Honer M, Schubiger PA. Molecular imaging with PET. Chem Rev. 2008;108:1501–16.
Article CAS PubMed Google Scholar
Zhu L, Ploessl K, Kung HF. PET/SPECT imaging agents for neurodegenerative diseases. Chem Soc Rev. 2014;43:6683–91.
Article CAS PubMed PubMed Central Google Scholar
Pavese N, Brooks DJ. Imaging neurodegeneration in Parkinson’s disease. Biochem Biophys Acta. 2009;1792:722–9.
Matthews DC, Lerman H, Lukic A, Andrews RD, Mirelman A, Wernick MN, Giladi N, Strother SC, Evans KC, Cedarbaum JM, Even-Sapir E. FDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage disease. Neuroimage Clin. 2018;20:572–9.
Article PubMed PubMed Central Google Scholar
Meyer PT, Frings L, Rücker G, Hellwig S. (18)F-FDG PET in Parkinsonism: Differential Diagnosis and Evaluation of Cognitive Impairment. J Nucl Med. 2017;58:1888–98.
Article CAS PubMed Google Scholar
Garraux G, Phillips C, Schrouff J, Kreisler A, Lemaire C, Degueldre C, Delcour C, Hustinx R, Luxen A, Destée A, Salmon E. Multiclass classification of FDG PET scans for the distinction between Parkinson’s disease and atypical parkinsonian syndromes. Neuroimage Clin. 2013;2:883–93.
留言 (0)